Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of guselkumab in pediatric participants
ISRCTN37514492Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of guselkumab in autoimmune colitis, Crohn's disease and juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Long-term safety and Adverse events. Started Oct 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
autoimmune colitisCrohn's diseasejuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on ISRCTN37514492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37514492.